Secondary cytotoxicity mediated by alveolar macrophages: A contribution to the total efficacy of nanoparticles in lung cancer therapy?

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 76, Issue 1, 2010, Pages 112-119

  Al Hallak, Kamal M H D ^a,b   Azarmi, Shirzad ^a,c   Anwar Mohamed, Anwar ^a   Roa, Wilson H ^a   Löbenberg, Raimar ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DAMASCUS UNIVERSITY   (Syrian Arab Republic)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytokines; Inflammation; Lung cancer; Macrophages; Nanoparticles

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BUCRILATE; DOXORUBICIN; GAMMA INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER THERAPY; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; HUMAN; HUMAN CELL; LUNG ALVEOLUS MACROPHAGE; LUNG CANCER; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; TH1 CELL; TREATMENT OUTCOME;

EID: 77955662556     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.05.002     Document Type: Article

References (58)

1. Gipps E.M., Groscurth P., Kreuter J., Speiser P.P. Distribution of polyhexylcyanoacrylate nanoparticles in nude mice over extended times and after repeated injection. J. Pharm. Sci. 1988, 77:208-209.
2. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
3. Illum L., Jones P.D., Baldwin R.W., Davis S.S. Tissue distribution of poly(hexyl 2-cyanoacrylate) nanoparticles coated with monoclonal antibodies in mice bearing human tumor xenografts. J. Pharmacol. Exp. Ther. 1984, 230:733-736.
4. Chiannilkulchai N., Ammoury N., Caillou B., Devissaguet J.P., Couvreur P. Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother. Pharmacol. 1990, 26:122-126.
5. Chiannilkulchai N., Driouich Z., Benoit J.P., Parodi A.L., Couvreur P. Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases. Sel. Cancer Ther. 1989, 5:1-11.
6. Azarmi S., Roa W.H., Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev. 2008, 60:863-875.
7. Barar J., Javadzadeh A.R., Omidi Y. Ocular novel drug delivery: impacts of membranes and barriers. Expert. Opin. Drug Deliv. 2008, 5:567-581.
8. Cosco D., Celia C., Cilurzo F., Trapasso E., Paolino D. Colloidal carriers for the enhanced delivery through the skin. Expert. Opin. Drug Deliv. 2008, 5:737-755.
9. Ely L., Roa W., Finlay W.H., Lobenberg R. Effervescent dry powder for respiratory drug delivery. Eur. J. Pharm. Biopharm. 2007, 65:346-353.
10. Gill S., Lobenberg R., Ku T., Azarmi S., Roa W., Prenner E.J. Nanoparticles: Characteristics, mechanisms of action, and toxicity in pulmonary drug delivery - a review. J. Biomed. Nanotechnol. 2007, 3:107-119.
11. Edwards D.A., Ben-Jebria A., Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J. Appl. Physiol. 1998, 85:379-385.
12. Desai T.R., Wong J.P., Hancock R.E., Finlay W.H. A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling. J. Pharm. Sci. 2002, 91:482-491.
13. Sham J.O., Zhang Y., Finlay W.H., Roa W.H., Lobenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm. 2004, 269:457-467.
14. Oberdorster G., Oberdorster E., Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 2005, 113:823-839.
15. Muhlfeld C., Rothen-Rutishauser B., Blank F., Vanhecke D., Ochs M., Gehr P. Interactions of nanoparticles with pulmonary structures and cellular responses. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 294:L817-L829.
16. Harmsen A.G., Muggenburg B.A., Snipes M.B., Bice D.E. The role of macrophages in particle translocation from lungs to lymph nodes. Science 1985, 230:1277-1280.
17. Montuenga L.M., Pio R. Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10. Eur. Respir. J. 2007, 30:608-610.
18. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 1999, 16:1564-1569.
19. Azarmi S., Tao X., Chen H., Wang Z., Finlay W.H., Lobenberg R., Roa W.H. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int. J. Pharm. 2006, 319:155-161.
20. Couvreur P., Kante B., Grislain L., Roland M., Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles II: doxorubicin-loaded nanoparticles. J. Pharm. Sci. 1982, 71:790-792.
21. Illum L., Khan M.A., Mak E., Davis S.S. Evaluation of carrier capacity and release characteristics for poly(butyl 2-cyanoacrylate) nanoparticles. Int. J. Pharm. 1985, 30:17-28.
22. Monza da Silveira A., Ponchel G., Puisieux F., Duchene D. Combined poly(isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs. Pharm. Res. 1998, 15:1051-1055.
23. Azarmi S., Lobenberg R., Roa W.H., Tai S., Finlay W.H. Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles. Drug Dev. Ind. Pharm. 2008, 34:943-947.
24. Hillaireau H., Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 2009, 66:2873-2896.
25. Kante B., Couvreur P., Dubois-Krack G., De Meester C., Guiot P., Roland M., Mercier M., Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles I: free nanoparticles. J. Pharm. Sci. 1982, 71:786-790.
26. Athlin L., Domellof L., Norberg B. Effect of therapeutic concentrations of anthracyclines on monocyte phagocytosis of yeast cells. Eur. J. Clin. Pharmacol. 1989, 36:155-159.
27. Evora C., Soriano I., Rogers R.A., Shakesheff K.N., Hanes J., Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J. Control. Release 1998, 51:143-152.
28. Kim D.W., Min H.S., Lee K.H., Kim Y.J., Oh D.Y., Jeon Y.K., Lee S.H., Im S.A., Chung D.H., Kim Y.T., Kim T.Y., Bang Y.J., Sung S.W., Kim J.H., Heo D.S. High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br. J. Cancer 2008, 98:1118-1124.
29. Yasuda I., Kato T., Asano F., Okubo K., Omar S., Kako N., Yasuda S., Sano K., Soehendra N., Moriwaki H. Mediastinal lymph node staging in potentially resectable non-small cell lung cancer: a prospective comparison of CT and EUS/EUS-FNA. Respiration 2009.
30. Videira M.A., Botelho M.F., Santos A.C., Gouveia L.F., de Lima J.J., Almeida A.J. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target. 2002, 10:607-613.
31. de Verdiere A.C., Dubernet C., Nemati F., Soma E., Appel M., Ferte J., Bernard S., Puisieux F., Couvreur P. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br. J. Cancer 1997, 76:198-205.
32. Panyam J., Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(d,l-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm. Res. 2003, 20:212-220.
33. Lenaerts V., Couvreur P., Christiaens-Leyh D., Joiris E., Roland M., Rollman B., Speiser P. Degradation of poly (isobutyl cyanoacrylate) nanoparticles. Biomaterials 1984, 5:65-68.
34. Tomoda H., Kishimoto Y., Lee Y.C. Temperature effect on endocytosis and exocytosis by rabbit alveolar macrophages. J. Biol. Chem. 1989, 264:15445-15450.
35. Bjerknes R. Exocytosis of zymosan particles by human phagocytes. Scand. J. Haematol. 1984, 33:197-206.
36. Hasegawa T., Iijima K., Hirota K., Nakajima T., Makino K., Terada H. Exact determination of phagocytic activity of alveolar macrophages toward polymer microspheres by elimination of those attached to the macrophage membrane. Colloids Surf. B Biointerfaces 2008, 63:209-216.
37. Majai G., Petrovski G., Fesus L. Inflammation and the apopto-phagocytic system. Immunol. Lett. 2006, 104:94-101.
38. Chung E.Y., Kim S.J., Ma X.J. Regulation of cytokine production during phagocytosis of apoptotic cells. Cell Res. 2006, 16:154-161.
39. Burke F., Balkwill F.R. Cytokines in animal models of cancer. Biotherapy 1996, 8:229-241.
40. Bosco M.C., Rapisarda A., Massazza S., Melillo G., Young H., Varesio L. The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1 alpha and -1 beta in macrophages. J. Immunol. 2000, 164:3283-3291.
41. Burke F. Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer. Cytokines Cell Mol. Ther. 1999, 5:51-61.
42. Driscoll K.E. Macrophage inflammatory proteins: biology and role in pulmonary inflammation. Exp. Lung Res. 1994, 20:473-490.
43. Biswas S.K., Sodhi A. Tyrosine phosphorylation-mediated signal transduction in MCP-1-induced macrophage activation: role for receptor dimerization, focal adhesion protein complex and JAK/STAT pathway. Int. Immunopharmacol. 2002, 2:1095-1107.
44. Biswas S.K., Sodhi A., Paul S. Regulation of nitric oxide production by murine peritoneal macrophages treated in vitro with chemokine monocyte chemoattractant protein 1. Nitric Oxide 2001, 5:566-579.
45. Wink D.A., Vodovotz Y., Laval J., Laval F., Dewhirst M.W., Mitchell J.B. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998, 19:711-721.
46. Maurer M., von Stebut E. Macrophage inflammatory protein-1. Int. J. Biochem. Cell Biol. 2004, 36:1882-1886.
47. Shiraishi K., Ishiwata Y., Nakagawa K., Yokochi S., Taruki C., Akuta T., Ohtomo K., Matsushima K., Tamatani T., Kanegasaki S. Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. Clin. Cancer Res. 2008, 14:1159-1166.
48. Thongphasuk P., Stremmel W., Chamulitrat W. Potent direct or TNF-α-promoted anticancer effects of 2,3-dehydrosilybin: Comparison study with silybin. Chemotherapy 2007, 54:23-30.
49. Itano S., Fuchimoto S., Orita K. Synergistic antitumor effects of natural human tumor necrosis factor and mouse interferon beta and gamma. Hiroshima J. Med. Sci. 1987, 36:219-225.
50. Yumura M. Macrophage migration inhibition-activity after implantation of methylcholanthrene-induced sarcoma, Ehrlich ascites cancer or mouse ascites hepatoma-134 cancer cells in mice. Acta Med. Okayama 1976, 30:37-48.
51. Gao B., Tsan M.F. Induction of cytokines by heat shock proteins and endotoxin in murine macrophages. Biochem. Biophys. Res. Commun. 2004, 317:1149-1154.
52. O'Byrne K. The link between inflammation and cancer: wounds that do not heal 2006, Springer.
53. Lee P.P., Zeng D., McCaulay A.E., Chen Y.F., Geiler C., Umetsu D.T., Chao N.J. T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood 1997, 90:1611-1617.
54. Dinarello C.A. Historical insights into cytokines. Eur. J. Immunol. 2007, 37(Suppl. 1):S34-S45.
55. Romagnani S. The Th1/Th2 paradigm. Immunol. Today 1997, 18:263-266.
56. Manzotti C., Audisio R.A., Pratesi G. Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin. Exp. Metastasis 1993, 11:5-14.
57. Shalaby M.R., Pennica D., Palladino M.A. An overview of the history and biologic properties of tumor necrosis factors. Springer Semin. Immunopathol. 1986, 9:33-37.
58. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., Oppenheim J.J., Murphy W.J. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96:34-40.